Concurrent control study of involved field intensity modulated radiotherapy in patients with esophageal carcinoma
10.3969/j.issn.1006-5725.2016.11.022
- VernacularTitle:食管癌调强放疗累及野照射的同期对照研究
- Author:
Duojie LI
;
Hongwei LI
;
Zhen CUI
;
Bin HE
;
Jingjing LIU
;
Hanfei CAI
;
Shimiao DUAN
;
Hao JIANG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Intensity modulated radiotherapy;
Involved field irradiation;
Failure pattern
- From:
The Journal of Practical Medicine
2016;32(11):1799-1802
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the treatment effect and failure patterns associated with different clinical target volume on patients with esophageal carcinoma treated with 5-filed intensity modulated radiotherapy (IMRT), and to determine whether involved field irradiation (IFI) is practicable in these patients. Methods A total of 88 patients with esophageal carcinoma between January 2012 to June 2014 underwent IMRT in our hospital, were divided into IFI group and elective nodal irradiation(ENI) group according to the CTV range for a concurrent control study. Results One-year and two-year survival rate in IFI group and ENI group were 75.0%, 45.5% and 70.5%, 43.2% respectively (P > 0.05). Local failure rate in IFI and ENI groups was 27.3% and 22.7% respectively, distant metastasis failure rates 22.7% and 18.2% respectively and regional failure rate outside the radiation field 11.4% and 4.5%, which showed no statistical difference (P > 0.05). Subgroup analysis indicated failure outside the radiation field tended to increase for primary lesion located in the up thoracic or clinical stageⅠ in IFI group. The volume dose histogram of lung V5, V20, V30 and mean lung dose of ENI group were greater than that of IFI group, while V5 of lung and the mean lung dose had statistical difference. Conclusions The survival rate and local control rate have no significant differencein IFI group and ENI group, so IFI is feasible for some esophageal carcinoma, but it should be cautious to choose IFI for those primary lesion located in the up thoracic or clinical stageⅠ.
